ArticleJACC. Case reports2026
Perugini Grade 3 Uptake Does Not Exclude AL Cardiac Amyloidosis: When Noninvasive Diagnosis Fails.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone scintigraphy has improved noninvasive diagnosis of cardiac amyloidosis, but interpretation remains challenging when monoclonal gammopathy is present. CASE SUMMARY: A 76-year-old man with heart failure with preserved ejection fraction, chronic kidney disease, permanent atrial fibrillation, and persistent troponin elevation underwent coronary angiography showing significant left anterior descending artery stenosis treated with percutaneous coronary intervention. Persistent symptoms, recurrent heart failure decompensations, disproportionate natriuretic peptide elevation, increased wall thickness, and apical sparing raised suspicion for infiltrative cardiomyopathy. Laboratory testing revealed monoclonal gammopathy. Tc-99m-pyrophosphate scintigraphy showed Perugini grade 3 uptake, strongly suggestive of transthyretin cardiac amyloidosis (ATTR-CA), but endomyocardial biopsy established light-chain (AL) cardiac amyloidosis. AL-directed therapy was initiated, but the patient died of severe pneumonia with respiratory failure. DISCUSSION: In the presence of monoclonal gammopathy, even Perugini grade 3 uptake does not establish ATTR-CA. Recent ischemic injury may further confound scintigraphic interpretation. TAKE-HOME MESSAGE: Tissue confirmation remains essential for accurate diagnosis and timely AL-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.